Lamberti, JS. Seven keys to relapse prevention in schizophrenia. J Psychiatr Pract
2001; 7: 253–9.
Wiersma, D, Nienhuis, FJ, Slooff, CJ, Giel, R.
Natural course of schizophrenic disorders: a 15-year follow up of a Dutch incidence cohort. Schizophr Bull
1998; 24: 75–85.
McGlashan, TH. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull
1988; 14: 515–42.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). APA, 1994.
Almond, S, Knapp, M, Francois, C, Toumi, M, Brugha, T.
Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry
2004; 184: 346–51.
Csernansky, JG, Schuchart, EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs
2002; 16: 473–84.
Hogarty, GE, Ulrich, RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res
1998; 32: 243–50.
Weiden, P, Mott, T, Curcio, N.
Recognition and management of neuroleptic noncompliance in schizophrenia. In Contemporary Issues in the Treatment of Schizophrenia (eds Shriqui, CL, Nasrallah, HA): 411–34. American Psychiatric Publishing, 1995.
Weiden, PJ, Zygmunt, A.
Medication noncompliance in schizophrenia. Part I: Assessment. J Prac Psych Behav Health
1997; 3: 106–10.
National Institute for Clinical Excellence. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia (Technology Appraisal No. 43). NICE, 2002.
National Collaborating Centre for Mental Health. Schizophrenia: The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated Edition) (National Clinical Guideline Number 82). British Psychological Society, Royal College of Psychiatrists, 2010.
Curtis, L, Netten, A.
Unit costs of Health and Social Care 2006. University of Kent, 2006.
British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary (issue 52). BMJ Group and Pharm Press, 2006.
Singleton, N, Bumpstead, R, O'Brien, M, Lee, A, Meltzer, H.
Psychiatric Morbidity among Adults living in Private Households, 2000: Summary Report. Office for National Statistics, 2001.
Robinson, D, Woerner, MG, Alvir, JM, Bilder, R, Goldman, R, Geisler, S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry
1999; 56: 241–7.
Kamali, M, Kelly, L, Gervin, M, Browne, S, Larkin, C, O'Callaghan, E.
Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. Psychiatr Serv
2001; 52: 161–6.
Fenton, WS, Blyler, CR, Heinssen, RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull
1997; 23: 637–51.
Adams, CE, Fenton, MKP, Quraishi, S, David, AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry
2001; 179: 290–9.
Schooler, NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry
2003; 64 (suppl 16): s14–7.
Knapp, M, King, D, Pugner, K, Lapuerta, P.
Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry
2004; 184: 509–16.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.